This strategy sets out ECRIN’s priorities over the next three years. It defines the six areas of focus for ECRIN and carves out a path to advance our mission and vision. For each of the goals set out in this plan, distinct actions have been identified that will be carried out over the next three years.
Through the strategic plan, ECRIN looks to answer, even anticipate the users’ needs, be leading-edge as well as recognised as the reference in the setup and management of multinational clinical trials in Europe.
Don't miss International Clinical Trials Day: 20 May 2021
The theme of this year's event is Platform Trials: Shift in Treatment, Testing and Collaboration. This new trial format raises many questions, changes our approach to conducting clinical trials and testing for appropriate treatments. Through this online conference, we hope to help you answer some of the questions that come to mind when considering this new methodology.
Join us as we celebrate the outcomes and tools from the PedCRIN project
As the PedCRIN project comes to a close we share the tools that have been developed through the project. REGISTER for a webinar and / or save the date for the final event.
The first webinar, Tools for the management of paediatric trials - Handling biosamples and assessing causality of adverse events, is now available for all.
ECRIN has launched the Covid-19 Marketplace. This new, online tool aims to search for similar trial protocols to collaborate with, and to share trial protocols in order to get in touch with clinical researchers interested in the same topic. The Covid-19 Marketplace is freely available for all scientific researchers working in clinical research, and in particular on Covid-19. The research questions submitted are approved for inclusion in the database by the ECRIN team, based on their capacity to answer the medical communities need to advance Covid-19 research, and then made searchable on the Marketplace platform.
The ECRIN Data Centre Certification is pleased to share that one of its previously certified data centres, AIBILI, Coimbra (Portugal), received approval by the ECRIN Independent Certification Board (ICB) for certification renewal.
No generic approach for sample size estimation can be made in personalised medicine when designing a stratification cohort. The approach for sample size estimation needs to be chosen according to the specific study type and goals as well as the parameters that influence the sample size. This workshop was the first in a series organised by the PERMIT project which will be used to elaborate the robust and reproducible recommendations for Personalised Medicine.
Among the achievements discussed, is the development of a sensitive data sharing toolbox. A new publication summarises the work carried out to date on the development of this toolbox and the necessary steps towards it implementation.
EOSC-Life is funded by the European Union’s Horizon 2020 Research and Innovation programme under Grant Agreement number 824087.
VACCELERATE project kick-off
The kick-off of the new Pan-European vaccine network was held on 5 March 2021. The network serves as a single entry-point for all stakeholders in COVID-19 vaccine development for phase 2 & 3 trials in Europe.
ECRAID-Base is funded by the European Union’s Horizon 2020 Research and Innovation programme under Grant Agreement number 965313.
EU-Africa PerMed project kick-off
The EU-Africa PerMed (Building links between Europe and Africa in Personalised Medicine) project kicked off with a full-day virtual meeting on March 4 2021. This four-year project aims to integrate African countries into ICPerMed activities.
CZECRIN and its partners coordinate national COVID-19 clinical research
CZECRIN and its partners coordinate several national multicentric COVID-19 clinical trials: REMED which looks to identify an effective daily dose of dexamethasone in adults with COVID-19 and moderate to acute respiratory distress syndrome and CoVigi, a phase IV study, which monitors vaccine efficacy and safety against COVID-19.
FCRIN - COVIREIVAC platform launches new trials
COVIREIVAC, the French vaccinal platform coordinated by Inserm and F-CRIN is being used for the clinical trial evaluating the efficacy of two doses of Janssen’s vaccine candidate, which began in February as well as other ambitious projects.
SCReN has moved its coordination unit from the Instituto de Investigación Sanitaria del Hospital Clínico San Carlos team to the Instituto de Investigación del Hospital Universitario La Paz team, IdiPaz. The new reorganisation will align the experience and capacity of SCReN's activities and will develop 11 working groups on key subjects for the network.
SCTO Symposium - Medical devices: Lost in Translation
Following a one-year delay and the transition period, the European Union’s new Medical Devices Regulation (MDR) will become fully applicable on 26 May 2021. For reasons of consistency, Switzerland’s revised and new legislation on medical devices will enter into force in stages as well.
The SCTO's Symposium will be held on 8 June 2021 and address the new requirements for medical devices as well as focus on the Swiss context. Registration is now open for this online event that will be held in English.
By subscribing to our newsletter, you have provided us with your name and email address. This personal data will be used solely for the purpose of keeping you up-to-date with ECRIN activities. We will keep your data for as long as your newsletter subscription is active. (Note: you may choose to unsubscribe at any time by clicking on the 'unsubscribe' link located at the bottom of our newsletter.)
To send you the newsletter, we use a very popular provider called MailChimp. If you subscribe to our newsletter, you consent that we send your contact information to Mailchimp, which stores your contact information in their servers.
Please be aware that Mailchimp has developed its own policy with respect to the GDPR and its own contractual terms and conditions. Please read their policy and if you do not agree with their policy, you must unsubscribe immediately from our newsletter. Should you have any questions concerning the way in which ECRIN is processing your data, please refer them to the following address: firstname.lastname@example.org